Tata Capital Healthcare Fund II, a private equity firm under the popular Tata Group, known for its focus on growth-stage healthcare organizations, has made a significant investment of $10 million in Apex Kidney Care (AKC), India’s second-highest dialysis chain. The investment, resulting in an undisclosed stake, was aimed at supporting Mumbai-based Apex Kidney Care in growing its dialysis services across the country.

In India, almost 21 million dialysis sessions are performed each year, accounting for less than 11% of total demand. This data highlights a considerable disparity caused by variables such as accessibility, price, and compliance issues. In March 2022, Tata Capital Healthcare Fund II made its maiden Investment in Deeptek, a health tech startup, and extended a $10 million commitment to Mumbai-based Oncocare Centre, a network of cancer treatment clinics.

"At TCHF II, we take a holistic approach to investing capital and backing companies like AKC that address glaring gaps in healthcare", said Vamesh Chovatia, Partner at Tata Funds Healthcare Fund II. We are excited to collaborate with AKC to provide high-quality, cost-effective services to nephrology patients. "We feel that India requires many more Apex-type firms to supply dialysis services and successfully meet the industry's healthcare requirement gap".

Apex Kidney Care CEO Indranil Roy Choudhury stated, "This is a defining moment for us at Apex Kidney Care, and we are honored to be associated with Tata Capital Healthcare Fund II". This collaboration will considerably enhance our service capabilities and will be important in accomplishing our vision of developing a renal care ecosystem for patients based on compassion, respect, transparency, and desired treatment results. "The funding of Tata Capital Healthcare Fund II would assist us in making dialysis and allied treatments accessible and affordable to everyone".